Hamilton R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Hamilton, New Jersey Businesses

Hamilton, New Jersey, is known for industries such as healthcare, education, retail, manufacturing, and technology. Top companies in the city include Robert Wood Johnson University Hospital Hamilton, a leading healthcare provider; Rider University, a major educational institution; Walmart, a significant retail employer; Siemens, a key player in the manufacturing sector; and Oracle, a prominent technology company. The R&D Tax Credit can help these industries save on taxes by encouraging innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 100 Horizon Center Boulevard, Hamilton, New Jersey provides R&D tax credit consulting and advisory services to Hamilton and the surrounding areas such as: Newark, Jersey City, Elizabeth, Edison, Woodbridge Township and Trenton.

If you have any questions or need further assistance, please call or email our local New Jersey Partner on (609) 900-2488.
Feel free to book a quick teleconference with one of our New Jersey R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Hamilton, New Jersey Patent of the Year – 2024/2025

Venenum Biodesign LLC has been awarded the 2024/2025 Patent of the Year for innovation in cancer treatment. Their invention, detailed in U.S. Patent No. 11883420, titled ‘Sting agonists for treating bladder cancer and solid tumors’, introduces a novel class of drugs designed to boost the immune system’s ability to attack tumors.

This breakthrough therapy activates the STING (Stimulator of Interferon Genes) pathway, a key component of the body’s innate immune response. By stimulating this pathway, the treatment prompts the immune system to recognize and destroy cancer cells more effectively.

The technology has the potential to significantly improve outcomes for patients with bladder cancer and other solid tumors. Traditional cancer therapies often struggle to target certain tumors, but STING agonists may offer a new route to activate immune defenses directly at the tumor site.

Venenum Biodesign’s patent covers specific small molecules optimized for potency, stability, and safety. These molecules can be administered in ways that maximize tumor exposure while limiting unwanted side effects, making them promising candidates for future clinical use.

With this patented approach, Venenum Biodesign is advancing a powerful tool in the fight against cancer. The innovation brings new hope for therapies that work with the body, not just against the disease.